Orexigen (OREX) Higher Early Following VIVUS (VVUS) Qsymia Approval; Arena (ARNA) Lower
Tweet Send to a FriendGet Alerts OREX Hot Sheet
Up)
Trade OREX Now!
Orexigen (Nasdaq: OREX) is popping higher early Wednesday following late-Tuesday approval of VIVUS (Nasdaq: VVUS) weight-management drug Qsymia.
Shares are up over 6.5 percent while VIVUS recently resumed trading and is indicated higher ahead of the bell.
Arena Pharma (Nasdaq: ARNA), which received FDA approval for its Belviq in June, is also lower ahead of the session.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares are up over 6.5 percent while VIVUS recently resumed trading and is indicated higher ahead of the bell.
Arena Pharma (Nasdaq: ARNA), which received FDA approval for its Belviq in June, is also lower ahead of the session.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Tesla (TSLA) Ramps Higher (GM)
- UPDATE: Viropharma, Inc. (VPHM) Said to Attract Acquisition Interest - Reuters
- Sony (SNE) Won't Consider Loeb's Entertainment Spinoff Proposal at AGM
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
